Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cinobufacin and Arterial Embolotherapy in Advanced Hepatoma
NCT01236690Phase 2Unknown
- Sponsor
- Changhai Hospital
- Start
- Nov 2010
- Primary completion
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cinobufacini in hepatocellular carcinoma (HCC), sponsored by Changhai Hospital. Primary endpoint: Objective Response Rate at 3 years. Status: unknown.
02
Drugs
cinobufacini
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01236690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01236690.